Developmental funds are a major source of flexible funding for the SKCCC. These funds have allowed the Center to strengthen its scientific programs and provide scientists the opportunity to explore innovative ideas and new collaborations. These funds are critical to maintaining and extending the research vitality of the scientific programs in the Cancer Center. Use of these funds is tightly linked to the formal planning and evaluation activities of the Center. A review of the priority of programmatic needs for new faculty recruitment by the Director, Associate Directors and Program Leaders has resulted in this estimated allocation of development funds during this next CCSG cycle to new faculty investigators $500,000 (67%), pilot projects $100,000 (13%), and shared resource development $150,000 (20%). We are requesting $750,000 in Developmental Funds. These funds will be instrumental in achieving the goals of SKCCC's strategic planning. Given the expansion in our research programs and sponsored funding (an increase of over 100% in the last five years), we believe this increase is justified.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-48
Application #
8117682
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
48
Fiscal Year
2010
Total Cost
$605,396
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Anchoori, Ravi K; Jiang, Rosie; Peng, Shiwen et al. (2018) Covalent Rpn13-Binding Inhibitors for the Treatment of Ovarian Cancer. ACS Omega 3:11917-11929
Shanbhag, Satish; Ambinder, Richard F (2018) Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin 68:116-132
Palsgrove, Doreen N; Brosnan-Cashman, Jacqueline A; Giannini, Caterina et al. (2018) Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association. Mod Pathol 31:1787-1800
Adler, B L; Pezhouh, M K; Kim, A et al. (2018) Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med 283:568-577
Kelley, Dylan Z; Flam, Emily L; Guo, Theresa et al. (2018) Functional characterization of alternatively spliced GSN in head and neck squamous cell carcinoma. Transl Res 202:109-119
Knapp, Emily A; Dean, Lorraine T (2018) Consumer credit scores as a novel tool for identifying health in urban U.S. neighborhoods. Ann Epidemiol 28:724-729
Forde, Patrick M; Chaft, Jamie E; Smith, Kellie N et al. (2018) Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. N Engl J Med 378:1976-1986
Cottrell, Tricia R; Duong, Anh T; Gocke, Christopher D et al. (2018) PD-L1 expression in inflammatory myofibroblastic tumors. Mod Pathol 31:1155-1163
Fackler, Mary Jo; Sukumar, Saraswati (2018) Quantitation of DNA Methylation by Quantitative Multiplex Methylation-Specific PCR (QM-MSP) Assay. Methods Mol Biol 1708:473-496
Converse, Paul J; Almeida, Deepak V; Tasneen, Rokeya et al. (2018) Shorter-course treatment for Mycobacterium ulcerans disease with high-dose rifamycins and clofazimine in a mouse model of Buruli ulcer. PLoS Negl Trop Dis 12:e0006728

Showing the most recent 10 out of 2393 publications